Cat. No. | Product name | CAS No. |
DC8704 |
Ca2+ channel agonist 1
Ca2+ channel agonist 1 is a N-type Ca2+ channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM. |
1402821-24-2 |
DC6701 |
Camptothecine
Camptothecin (CPT) is a potent DNA enzyme topoisomerase I (topo I) inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231. |
7689-03-4 |
DC8553 |
Canertinib
Featured
Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3. CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB |
267243-28-7 |
DC9095 |
Carboplatin
Featured
Carboplatin is a chemotherapy drug by binding to DNA and interfering with the cell's repair mechanism. |
41575-94-4 |
DC8776 |
CCT 137690
CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
1095382-05-0 |
DC12283 |
CCT020312
CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK). |
324759-76-4 |
DC9399 |
CCT241533 (hydrochloride)
CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM. |
1431697-96-9 |
DC8324 |
CCT244747
Featured
CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies. |
1404095-34-6 |
DC9968 |
CCT251545
Featured
CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM. |
1661839-45-7 |
DC9969 |
CCT251921
CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). |
1607837-31-9 |
DC11158 |
CDK12 inhibitor 2
CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9. |
|
DC11872 |
CDK12 inhibitor E9 S-isomer
CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
2020052-55-3 |
DC8596 |
Cdk4/6 Inhibitor IV
Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively) |
359886-84-3 |
DC9478 |
CDK9-IN-1
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection. |
1415559-43-1 |
DC9390 |
CDK-IN-2
Featured
CDK-IN-2 is a potent and sepecific CDK inhibitor. |
1269815-17-9 |
DC10011 |
Centrinone-B
Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM). |
1798871-31-4 |
DC2099 |
cis-Diaminedichloroplatinum
Featured
Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. |
15663-27-1 |
DC11004 |
CLK2 inhibitor Indazole1
CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases. |
|
DC9799 |
CNDAC
Featured
CNDAC is the active component of sapacitabine. |
135598-68-4 |
DC10430 |
COH29
COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with an IC50 of 8 μM in KB cell. |
1190932-38-7 |
DC2085 |
Compound 401
Featured
Compound 401 is a cell-permeable pyrimido-isoquinolinone compound that acts as a potent, reversible, and ATP-competitive inhibitor of DNA-PK (IC50 = 280 nM) with ~19-fold selectivity over FRAP (mTOR) (IC50 = 5.3 µM). |
168425-64-7 |
DC11164 |
Compound 919278
Compound 919278 is a specific inhibitor of lymphotoxin β receptor (LTβR, IC50=0.169 uM), and TNF receptor superfamily member 12A (FN14)-dependent nuclear translocation of p52 (IC50=0.167 uM) via inhibiting CDK12/CCNK, does not inhibit the TNF-α-mediated nuclear translocation of p65 (RelA). |
2189366-77-4 |